Worldwide sales increased 2.3% to of $7.77 billion. The results were benefited by the higher sales from Medical Devices and Diagnostics businesses. Sales from Medical Devices grew 6.7% year-over-year. In Electrophysiology, the 16.7% growth was led by strong performance in cardiac mapping and ablation catheters. The 12.4% growth in Structural Heart was driven by several product areas across Abbott’s broad portfolio. In Diabetes Care, sales jumped 28.3%, led by rapid market uptake of FreeStyle Libre, which removes the need for routine fingersticks for people with diabetes. Source: https://news.alphastreet.com/abbott-laboratories-q4-2018-earnings-results-abt-stock/
Impressive data to say the least. Abbott may finally have taken the corner and will be on the move in 2019!
Looking forward to earnings transcripts! St. Jude and Libre certainly performed! Thankful stockholder Dump the Junk Miles!
